System | Type | Disorder | Pubmed |
neurology | neurodegenerative | huntington chorea |  |
SIRT2 inhibition is a promising avenue for HD therapy |
neuromuscular | myopathy | congenital |  |
SIRT2 inhibitors and AMPK inhibitors as potential therapeutics for OPMD and perhaps other muscular dystrophies and polyAla diseases |
cancer | | |  |
utilization of sirtuin activators that specifically target SIRT2 could serve as potential anticancer therapy |
miscelleaneous | | |  |
SIRT2 targeting may be therapeutically beneficial in diseases where aggregation of misfolded proteins is central to disease pathogenesis |
neurology | neurodegenerative | |  |
viable molecular target for neuroprotective therapy. |
neurology | neurodegenerative | |  |
therapeutic target in the most prevalent neurodegenerative diseases that undergo with axonal degeneration associated with redox and energetic dyshomeostasis |
cardiovascular | aquired | |  |
potential target for therapeutic interventions in aging- and stress-induced cardiac hypertrophy |
cancer | hemopathy | |  |
SIRT2 serves as a promising target for further therapeutic investigations |
neurology | neurodegenerative | Parkinson/dementia Parkinsonism |  |
inhibition of Sirtuin 2 expression may be a neuroprotective measure in Parkinson's disease |